The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Cristina Ponti(University of Milan), Dario Ballinari(Nerviano Medical Sciences), Paola Magnaghi(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Andrea Sartore‐Bianchi(University of Milan), Salvatore Siena(University of Milan), Roberta Bosotti(Human Technopole), Silvio Veronese(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Laura Raddrizzani(Nerviano Medical Sciences), Tiziano Bandiera(Nerviano Medical Sciences), Rachele Alzani(Nerviano Medical Sciences), Patrizia Banfi(Nerviano Medical Sciences), Eduard Felder, Fabio Gasparri(Nerviano Medical Sciences), Daniele Casero(Nerviano Medical Sciences), Maria Beatrice Saccardo(Nerviano Medical Sciences), Enrico Pesenti, Andrea Borgia(Nerviano Medical Sciences), Andrea Milani(Nerviano Medical Sciences), Marcello Gambacorta(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Rosaria Cammarota(Nerviano Medical Sciences), Alessio Somaschini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Marco A. Pierotti(Società Italiana di Nefrologia)
Cited by 156
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Intragenic ERBB2 kinase mutations in tumours
|Nature|2004|790